Wolfe Research initiated coverage of Natera with an Outperform rating and $70 price target. The combination of a robust growth outlook, large and expanding TAMs, a growing competitive moat via scientific data generation and commercial prowess, solid operational execution with a path to cash, and “pristine” Street management position the company to Outperform, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NTRA:
- Natera says court denies CareDX’s motion for summary judgment on patents
- Natera participates in a conference call with JPMorgan
- Morgan Stanley Says These 3 Stocks Are Top Picks for 2024
- Natera enters oncology research agreement with Merck
- Natera upgraded to Strong Buy from Outperform at Raymond James